Skip to main navigation Skip to search Skip to main content

Hmg-coa reductase inhibitors (Statins) and their drug interactions involving cyp enzymes, p-glycoprotein and oatp transporters-an overview

  • Anna University

Research output: Contribution to journal › Review article › peer-review

72 Scopus citations

Abstract

Background: Hydroxymethyl glutaryl-CoA (HMG-CoA) reductase inhibitors (Statins) are used to treat dyslipidemia. Generally, the statins are the substrates of CYP enzymes, P-glycoprotein (P-gp), and organic anion transporting polypeptides transporters (OATP1B1). Objective: This review article focuses on the clinical significance of statins, and their interactions in real prac-tice. Methods: The databases like Medline/PubMed Central/PubMed, Google Scholar, Science Direct, Cochrane Li-brary, Directory of open access journals (DOAJ), and reference lists were searched to identify relevant articles. Results: Most of the drug interactions of statins result in elevated plasma concentrations and toxicity of statins due to the inhibition of CYP3A4, P-gp and/or OATP1B1 transporters. The toxicity of statins includes myopa-thy, rhabdomyolysis, elevated liver enzymes, acute kidney injury, and diabetes. The statins like simvastatin, lo-vastatin, and atorvastatin are substrates of CYP3A4 enzyme and P-glycoprotein and their concomitant use with the drugs inhibiting or inducing them would result in changes in plasma concentrations and toxicity/efficacy. However, the statins like pravastatin, rosuvastatin and pitavastatin are not substrates of CYP enzymes and hence the concomitant use of CYP inhibitors or inducers does not affect them. Almost all the statins are the sub-strates of OATP1B1 transporter, and the co-prescription of inhibitors of OATP1B1 elevates the plasma concentrations and muscle toxicity of statins. Conclusion: Understanding the interacting potential of each statin will enable the prescribers, pharmacists, and other health care professionals to use statins effectively without compromising patient safety.

Original languageEnglish
Pages (from-to)328-341
Number of pages14
JournalCurrent Drug Metabolism
Volume22
Issue number5
DOIs
StatePublished - Apr 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CYP3A4
  • Drug interactions
  • HMG-CoA reductase inhibitors
  • OATP1B1 transporter
  • P-glycoprotein
  • Statin

Fingerprint

Dive into the research topics of 'Hmg-coa reductase inhibitors (Statins) and their drug interactions involving cyp enzymes, p-glycoprotein and oatp transporters-an overview'. Together they form a unique fingerprint.

Cite this